Multiple Sclerosis Relapsing-remitting
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis Relapsing-remitting.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-30EMA Authorised: Mayzent (siponimod fumaric acid) — Novartis Europharm Limited
Mayzent (siponimod fumaric acid) has been authorised in the EU for relapsing-remitting multiple sclerosis.
-
EMA approval · 2026-07-01EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited
Teriflunomide Viatris has been authorised for relapsing-remitting multiple sclerosis in the EU.
-
EMA approval · 2026-06-12EMA Authorised: Fingolimod Mylan (Fingolimod) — Mylan Pharmaceuticals Limited
Fingolimod Mylan has been authorised for multiple sclerosis, relapsing-remitting, by the EMA.
-
EMA approval · 2026-02-24EMA Authorised: Teriflunomide Accord (teriflunomide) — Accord Healthcare S.L.U.
The EMA authorised Teriflunomide Accord (teriflunomide) for relapsing-remitting multiple sclerosis. This represents approval of a generic te…
-
EMA approval · 2025-11-24EMA Authorised: Mayzent (siponimod fumaric acid) — Novartis Europharm Limited
The EMA authorised Mayzent (siponimod) for relapsing-remitting multiple sclerosis in the EU, with Novartis Europharm Limited as the marketin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.